CytomX Therapeutics Inc
CTMX2.390USD
-0.010-0.42%
收盘 07/28, 16:00（美东）报价延迟15分钟
192.68M总市值
4.63市盈率 TTM
关于 CytomX Therapeutics Inc 公司
CytomX Therapeutics, Inc. 是一家临床阶段、专注于肿瘤学的生物制药公司，致力于开发旨在定位于肿瘤微环境的新型条件激活生物制剂。该公司正在利用其 PROBODY 治疗技术平台推进潜在的同类首创和同类最佳抗体疗法。其产品线包括多种治疗方式的治疗候选药物，包括抗体-药物偶联物 (ADC)、T 细胞接合剂和免疫调节剂（如细胞因子）。其临床阶段产品线包括 CX-904、CX-2051 和 CX-801。CX-904 是一种条件激活的 T 细胞接合抗体，靶向肿瘤细胞上的表皮生长因子受体和 T 细胞上的 CD3 受体，并与安进公司建立了全球联合开发联盟。 CX-2051 是一种针对上皮细胞粘附分子 (EpCAM) 的条件激活 ADC，具有适用于多种表达 EpCAM 的上皮癌的潜在适用性。
公司简介
公司代码CTMX
公司名称CytomX Therapeutics Inc
上市日期Oct 08, 2015
成立日期2010
CEODr. Sean A. Mccarthy, Ph.D.
员工数量119
证券类型Ordinary Share
年结日Oct 08
公司地址151 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16505153185
网址https://cytomx.com/
公司代码CTMX
上市日期Oct 08, 2015
成立日期2010
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Ashworth, Ph.D.
Dr. Alan Ashworth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Robert (Jim) Meyers
Mr. James Robert (Jim) Meyers
Independent Director
Independent Director
--
--
Dr. Sean A. Mccarthy, Ph.D.
Dr. Sean A. Mccarthy, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
50.92M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月12日 周六
更新时间: 7月12日 周六
持股股东
股东类型
持股股东
持股股东
占比
Point72 Asset Management, L.P.
8.31%
VR Adviser, LLC
8.25%
Longitude Capital Management Co., LLC
7.32%
Tang Capital Management, LLC
4.26%
The Vanguard Group, Inc.
3.25%
Other
68.61%
持股股东
持股股东
占比
Point72 Asset Management, L.P.
8.31%
VR Adviser, LLC
8.25%
Longitude Capital Management Co., LLC
7.32%
Tang Capital Management, LLC
4.26%
The Vanguard Group, Inc.
3.25%
Other
68.61%
股东类型
持股股东
占比
Hedge Fund
20.39%
Venture Capital
16.21%
Investment Advisor
6.07%
Investment Advisor/Hedge Fund
3.98%
Individual Investor
0.67%
Research Firm
0.44%
Corporation
0.24%
Pension Fund
0.02%
Other
51.98%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
172
81.76M
51.90%
+8.85M
2025Q1
180
46.88M
32.26%
-27.51M
2024Q4
187
47.68M
60.93%
-26.52M
2024Q3
193
52.18M
66.81%
-19.54M
2024Q2
203
57.59M
74.04%
-4.03M
2024Q1
239
45.58M
66.89%
-10.30M
2023Q4
245
33.58M
50.13%
-26.30M
2023Q3
276
33.60M
50.33%
-37.55M
2023Q2
290
35.13M
52.97%
-38.77M
2023Q1
304
36.85M
55.65%
-34.99M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Point72 Asset Management, L.P.
13.09M
8.31%
+10.44M
+394.13%
May 13, 2025
VR Adviser, LLC
12.99M
8.25%
+12.99M
--
May 13, 2025
Longitude Capital Management Co., LLC
11.54M
7.32%
+11.54M
--
May 13, 2025
Tang Capital Management, LLC
6.72M
4.26%
-593.93K
-8.12%
Mar 31, 2025
The Vanguard Group, Inc.
5.12M
3.25%
-44.93K
-0.87%
Mar 31, 2025
Prosight Capital
3.93M
2.49%
+25.01K
+0.64%
Mar 31, 2025
Acadian Asset Management LLC
3.23M
2.05%
+96.99K
+3.09%
Mar 31, 2025
Millennium Management LLC
2.83M
1.79%
-394.74K
-12.26%
Mar 31, 2025
Woodline Partners LP
1.66M
1.05%
+1.66M
--
Mar 31, 2025
Laurion Capital Management LP
1.29M
0.82%
+45.32K
+3.63%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Formidable ETF
5.09%
iShares Micro-Cap ETF
0.05%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Formidable ETF
占比5.09%
iShares Micro-Cap ETF
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
